10-Q: Keros Therapeutics Reports Q3 Loss, Initiates $375M Capital Return

Keros Therapeutics reported a net loss of $7.3 million for Q3 2025, alongside a $110.5 million net income for the nine months ended September 30, 2025, driven by the Takeda license agreement, and announced a $375 million capital return plan to stockholders.

Summary

• Keros Therapeutics reported a net loss of $7.3 million for the three months ended September 30, 2025, compared to a net loss of $53.0 million for the same period in 2024.
• The company achieved a net income of $110.5 million for the nine months ended September 30, 2025, a significant improvement from a net loss of $141.3 million for the same period in 2024, primarily driven by the Takeda license agreement.
• Total revenue increased to $14.3 million for Q3 2025 (from $0.4 million in Q3 2024) and to $243.7 million for the nine months ended September 30, 2025 (from $0.5 million in 9M 2024), largely due to the Takeda agreement.
• Research and development (R&D) expenses decreased by $29.7 million to $19.5 million for Q3 2025, and by $16.3 million to $111.7 million for the nine months ended September 30, 2025, primarily due to reduced spending on KER-065, cibotercept, and elritercept as activities transition to Takeda, along with a reduction in headcount.
• General and administrative (G&A) expenses increased slightly to $10.1 million for Q3 2025 (from $9.8 million in Q3 2024) and to $35.1 million for the nine months ended September 30, 2025 (from $30.1 million in 9M 2024).
• Cash and cash equivalents stood at $693.5 million as of September 30, 2025.
• The company announced a plan to return $375.0 million of excess capital to stockholders, including a $180.6 million repurchase from ADAR1 Capital Management and Pontifax Venture Capital, and a $194.4 million issuer tender offer.
• A corporate restructuring in May 2025 reduced the workforce by approximately 45%, incurring $3.1 million in one-time employee termination benefits.
• The Phase 3 RENEW clinical trial for elritercept in lower-risk MDS dosed its first patient in July 2025, triggering a $10 million milestone payment from Takeda.
• KER-065 received Orphan Drug Designation for Duchenne muscular dystrophy (DMD) in August 2025.
• The Phase 2 clinical trial for cibotercept in PAH (TROPOS trial) was terminated early in January 2025 due to pericardial effusion adverse events, leading to deprioritization of cibotercept.

Sentiment

Score: 7

Explanation: The company achieved a significant net income for the nine-month period due to the Takeda licensing agreement, substantially improving its cash position and enabling a large capital return to stockholders. This demonstrates strong strategic execution in monetizing an asset. However, the quarter itself still showed a net loss, a key program (cibotercept) was terminated due to safety, and the company faces inherent risks of a clinical-stage biopharmaceutical company, including the need for future funding and successful clinical development of remaining candidates. The workforce reduction also indicates a significant shift in operational strategy.

Positives

• Achieved a significant net income of $110.5 million for the nine months ended September 30, 2025, primarily from the Takeda license agreement.
• Reported a substantial increase in total revenue for both the three and nine months ended September 30, 2025, driven by the Takeda agreement.
• Maintained a strong cash and cash equivalents position of $693.5 million as of September 30, 2025.
• Initiated a $375.0 million capital return plan to stockholders, demonstrating commitment to shareholder value.
• Dosed the first patient in the Phase 3 RENEW clinical trial for elritercept, triggering a $10 million milestone payment from Takeda.
• KER-065 received Orphan Drug Designation for Duchenne muscular dystrophy, potentially offering financial incentives and market exclusivity.
• Reduced R&D expenses for the quarter and nine-month period, reflecting strategic prioritization and cost management.
• Management believes existing cash and cash equivalents (less capital return) will fund operations into the first half of 2028.

Negatives

• Incurred a net loss of $7.3 million for the three months ended September 30, 2025.
• Deprioritized the cibotercept program and terminated its Phase 2 TROPOS trial early due to unanticipated pericardial effusion adverse events.
• Implemented a corporate restructuring involving a reduction in force of approximately 45% of the workforce, incurring $3.1 million in one-time employee termination benefits.
• The capital return plan will diminish cash reserves, which may impact the ability to advance clinical development of product candidates.
• The company has a limited operating history and has incurred net losses in every year since its inception (except for the nine months ended September 30, 2025, due to the one-time Takeda payment).
• Dependence on third-party collaborations for commercialization of elritercept, with risks if partners are unsuccessful or terminate agreements.

Risks

• Limited operating history and anticipated continued net losses in the future.
• Need for substantial additional funding to complete development and commence commercialization of product candidates; failure to obtain capital may force delays or elimination of operations.
• Heavy dependence on the success of product candidates (KER-065, elritercept), which are in clinical development; inability to advance or commercialize them would materially harm the business.
• Clinical trials are lengthy, expensive, and have uncertain outcomes; delays or inability to complete development and commercialization of KER-065, elritercept, or future candidates.
• Inability to successfully commercialize any approved product candidate or significant delays in doing so.
• Significant competition from other biotechnology and pharmaceutical companies.
• Difficulty and cost in protecting intellectual property; inability to ensure protection.
• Reliance on third parties (clinical investigators, laboratories, CROs) to conduct preclinical studies and clinical trials; failure to carry out duties or meet deadlines could substantially harm the business.
• Reliance on third parties to supply and manufacture product candidates; disruptions could stop, delay, or reduce profitability.
• Dependence on Takeda and Hansoh collaborations for elritercept commercialization; loss of significant potential revenue if they are unsuccessful.
• Current and future collaborations are important; inability to enter new ones or unsuccessful existing ones could adversely affect the business.
• Public health crises could adversely impact business, preclinical studies, and clinical trials.
• Product candidates may be associated with serious adverse, undesirable, or unacceptable side effects or safety risks, delaying or halting development or preventing marketing approval.
• Difficulty enrolling patients in clinical trials could cause delays or prevent advancement.
• Interim, topline, and preliminary data may change as more data become available and are subject to audit and verification.
• Preclinical development is uncertain; programs may experience delays or never advance to clinical trials.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable; inability to obtain approval would substantially harm the business.
• FDA and comparable foreign regulatory authorities may not accept data from trials conducted outside their jurisdiction.
• Ongoing regulatory obligations and review post-approval, with potential for significant additional expense and penalties for non-compliance.
• Approved biologics (KER-065, elritercept) may face competition from biosimilars approved through abbreviated pathways, potentially shortening exclusivity.
• Exposure to costly and damaging product liability claims.
• Limited resources necessitate prioritizing certain product candidates, which may prove to be wrong decisions.
• Market opportunities for product candidates may be smaller than believed.
• Product candidates may be subject to unfavorable third-party coverage and reimbursement practices and pricing regulations.
• Disruptions at government agencies (FDA, SEC) could hinder regulatory activities.
• Business operations and relationships subject to healthcare regulatory laws, exposing the company to penalties.
• Highly dependent on key personnel; failure to attract, motivate, and retain qualified personnel.
• Corporate restructuring may not result in anticipated savings, could incur greater costs, or disrupt business.
• Need to grow the organization, with potential difficulties in managing this growth.
• Internal computer systems or those of contractors failing or suffering security incidents could lead to adverse consequences.
• Subject to stringent and evolving U.S. and foreign data privacy and security laws and regulations.
• Employees, contractors, etc., may engage in misconduct or improper activities.
• Risks associated with operating business internationally.
• Subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws.
• Failure to comply with environmental, health, and safety laws.
• Changes in tax laws or regulations.
• Ability to use NOL carryforwards and tax credit carryforwards may be subject to limitation.
• Market price of common stock is volatile.
• Subject to securities class action litigation.
• Future sales and issuances of common stock could result in dilution.
• No intention to pay dividends.
• Capital allocation strategy may not be effective at enhancing stockholder value.
• Executive officers, directors, and significant stockholders can exercise significant influence.
• Stockholder rights plan and corporate charter provisions could make acquisition more difficult.
• Exclusive forum provisions in corporate charter documents.

Future Outlook

The company expects to initiate a Phase 2 clinical trial of KER-065 in patients with Duchenne muscular dystrophy in the first quarter of 2026. Takeda plans to advance elritercept (KER-050) into a Phase 3 clinical trial in patients with myelodysplastic syndromes. The company anticipates continuing to incur significant operating losses and negative operating cash flows for the foreseeable future, with R&D expenses expected to increase for ongoing and new clinical trials, except for elritercept-related expenses which are projected to decrease once fully transitioned to Takeda. Management believes existing cash and cash equivalents, after accounting for the $375.0 million capital return, will fund operating expenses and capital expenditure requirements into the first half of 2028. Additionally, the company plans to distribute 25% of any net cash proceeds received on or before December 31, 2028, from the Takeda Agreement to its stockholders.

Management Comments

• Management believes that the Company’s existing cash and cash equivalents as of September 30, 2025, less $375.0 million of excess capital that the Company's board of directors has determined to return to its stockholders, will allow the Company to continue its operations for at least the next 12 months.
• We expect to continue to generate operating losses and negative operating cash flows for the foreseeable future in connection with our ongoing activities.
• We expect that elritercept-related expenses will be eliminated once transitioned to Takeda.
• We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.
• We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.

Industry Context

The biopharmaceutical industry is characterized by intense competition and rapid innovation, with Keros Therapeutics competing against major multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical companies, and academic institutions. The company's target indications, such as Duchenne muscular dystrophy (DMD) and myelodysplastic syndromes (MDS), are areas with existing approved therapies and numerous candidates in development from competitors like Sarepta Therapeutics, PTC Therapeutics, Merck, Bristol-Myers Squibb, and GSK. The industry is also navigating broader economic challenges including inflation, rising interest rates, and geopolitical tensions, which could impact operating costs and access to financing. Evolving regulatory landscapes in the EU and UK, along with U.S. healthcare legislation aimed at cost reduction and drug pricing, present additional complexities and potential pressures on market access and profitability for new therapies.

Comparison to Industry Standards

• In Duchenne Muscular Dystrophy (DMD), Keros's KER-065 is in Phase 1, while competitors have FDA-approved corticosteroids (EMFLAZA by PTC Therapeutics, Agamree by Catalyst Pharmaceuticals), exon skipping drugs (EXONDYS 51, VYONDYS 53, AMONDYS 45 by Sarepta; VILTEPSO by Nippon Shinyaku), and gene therapies (ELEVIDYS by Sarepta, which recently had a temporary shipment pause). Other companies like REGENXBIO Inc., Solid Biosciences Inc., Avidity Biosciences, Inc., Wave Life Sciences Ltd., Dyne Therapeutics, Inc., and Edgewise Therapeutics, Inc. are also developing gene therapies, RNA-targeted treatments, and myosin ATPase inhibitors, respectively.
• For anemia in MDS and myelofibrosis, Keros's elritercept (KER-050) is advancing to Phase 3. Existing approved therapies include Reblozyl (Merck & Co. Inc., Bristol-Myers Squibb Company) for anemia in lower-risk MDS and beta thalassemia, Ojjaara (GSK plc) for myelofibrosis with anemia, and imetelstat (RYTELO) (Geron Corporation) for lowto intermediate-1 risk MDS with transfusion-dependent anemia. Pacritinib (Vonjo) (CTI BioPharma Corp./Swedish Orphan Biovitrum AB) is approved for myelofibrosis with low platelet counts. Incyte Corporation and Geron Corporation also have product candidates in development for myelofibrosis.
• In the broader TGF-beta signaling pathway, Keros competes with companies like Scholar Rock Holding Corporation, Biogen Inc., and Regeneron Pharmaceuticals, Inc., which are also developing product candidates targeting these pathways.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material arbitration or legal proceedings.

Related Party Transactions

• On October 15, 2025, the company entered into stock purchase agreements with certain entities affiliated with ADAR1 Capital Management and Pontifax Venture Capital to repurchase 10,176,595 shares of common stock for an aggregate purchase price of $180.6 million at $17.75 per share. Tomer Kariv and Ran Nussbaum, who resigned from the board, are affiliated with Pontifax Venture Capital.

Stakeholder Impact

• Shareholders: Positive impact from the $375.0 million capital return plan (share repurchases and tender offer), potentially enhancing shareholder value. However, the capital return will diminish cash reserves, which could impact future development. Dilution risk from future equity issuances and existing equity incentive plans. Volatility in stock price is expected.
• Employees: Significant negative impact due to the corporate restructuring in May 2025, which involved a reduction in force of approximately 45% of the workforce. This could lead to reduced morale and difficulties in attracting/retaining talent.
• Patients: Potential benefit from continued development of KER-065 for DMD and elritercept for MDS/myelofibrosis. Negative impact for patients relying on cibotercept due to its deprioritization.
• Collaborators (Takeda, Hansoh): Continued collaboration for elritercept, with Takeda advancing to Phase 3. Risks exist if collaborators are unsuccessful or terminate agreements.
• Creditors: No specific impact mentioned, but a strong cash position and capital return could be viewed positively or negatively depending on the long-term financial strategy.

Next Steps

• Initiate a Phase 2 clinical trial of KER-065 in patients with Duchenne muscular dystrophy in the first quarter of 2026.
• Takeda plans to advance elritercept (KER-050) into a Phase 3 clinical trial in patients with myelodysplastic syndromes.
• Substantially complete the 2025 Restructuring by the fourth quarter of 2025.
• Continue to incur significant operating losses and negative operating cash flows for the foreseeable future.
• Issuer tender offer to repurchase up to $194.4 million of common stock at $17.75 per share, commenced October 20, 2025.
• Distribute 25% of any net cash proceeds received on or before December 31, 2028, from the Takeda Agreement to stockholders.

Key Dates

Recommendation

The company has demonstrated strong strategic execution by securing a significant licensing deal with Takeda, leading to a substantial net income for the nine-month period and a robust cash position. The decision to return $375 million in excess capital to stockholders through repurchases and a tender offer is a positive signal for shareholder value. However, the early termination of the cibotercept program due to safety concerns and the associated workforce reduction highlight the inherent risks in biopharmaceutical development. While KER-065 and elritercept show promise with ongoing clinical trials and orphan drug designation, the company still faces significant R&D expenses, intense competition, and the need for future funding. The stock is likely to experience volatility due to these mixed signals and the ongoing capital return process. A 'hold' recommendation is appropriate as investors should monitor the progress of KER-065 and elritercept, the successful execution of the capital return, and the company's ability to manage its reduced workforce and future funding needs.

Keywords

Keros Therapeutics, KROS, Biopharmaceutical, Clinical-stage, KER-065, Duchenne Muscular Dystrophy, DMD, Elritercept, KER-050, Myelodysplastic Syndromes, MDS, Myelofibrosis, TGF-beta, Takeda Pharmaceuticals, Hansoh Healthtech, Capital Return, Share Repurchase, Tender Offer, Corporate Restructuring, Workforce Reduction, Orphan Drug Designation, Clinical Trials, Drug Development, SEC Filing, 10-Q